Cargando…
Inflammatory Mediators of Hepatic Steatosis
Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming a world-wide public health problem. NAFLD represents a spectrum of disease ranging from “simple steatosis”, which is considered relatively benign, to nonalcoholic steatohepatitis and to NAFLD-associated cirrhosis and end-stage liver diseas...
Autores principales: | Hijona, Elizabeth, Hijona, Lander, Arenas, Juan I., Bujanda, Luis |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2840375/ https://www.ncbi.nlm.nih.gov/pubmed/20300479 http://dx.doi.org/10.1155/2010/837419 |
Ejemplares similares
-
Pterostilbene Reduces Liver Steatosis and Modifies Hepatic Fatty Acid Profile in Obese Rats
por: Aguirre, Leixuri, et al.
Publicado: (2019) -
Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo models
por: Hijona, Elizabeth, et al.
Publicado: (2012) -
Resveratrol inhibits nonalcoholic fatty liver disease in rats
por: Bujanda, Luis, et al.
Publicado: (2008) -
Effect of resveratrol on alcohol-induced mortality and liver lesions in mice
por: Bujanda, Luis, et al.
Publicado: (2006) -
Novel equation to determine the hepatic triglyceride concentration in humans by MRI: diagnosis and monitoring of NAFLD in obese patients before and after bariatric surgery
por: Jiménez-Agüero, Raúl, et al.
Publicado: (2014)